eMultipleSclerosis Review

In the clinical trials of new MS medications and procedures, why has the participation of racial and ethnic minority individuals been so low? Is it a difficulty with outreach? Are the patient barriers to participation underrecognized and underaddressed? Does historical mistrust of the medical community remain a strong negative? What should clinicians and trial designers do to increase diversity to...

The long-anticipated advances in therapeutic treatments to improve outcomes in both relapsing and progressive MS are coming closer to fruition. Although much of the evidence is still preclinical, the variety and scope of the ongoing research promises to provide new and novel options to manage this disease in the relatively near future. Take our  post-test  to claim CME credits (https://e...

The long-anticipated advances in therapeutic treatments to improve outcomes in both relapsing and progressive MS are coming closer to fruition. Although much of the evidence is still preclinical, the variety and scope of the ongoing research promises to provide new and novel options to manage this disease in the relatively near future. Take our  post-test  to claim CME credits (https://e...

Giving birth and raising a family. For many people with MS, the path to achieving those goals contains more questions than answers. Questions about timing — which should come first, pregnancy or disease stability on a DMT? Questions about genetics — can MS be passed on to the baby? Questions about fertility — is in vitro fertilization safe and effective, and how much does it increase disease activ...

In this issue: Fatigue. It’s one of the most common complaints providers hear from their patients with MS. It interferes with virtually every aspect of a patient’s life. What can clinicians do to better identify MS fatigue? And what do they need to know to better provide management effectively tailored to each patient? Take our  post-test  to claim CME credits (https://elit.dkbmed.com/is...

In this issue: POMS. Pediatric Onset Multiple Sclerosis: children and adolescents with symptoms indicating a diagnosis of multiple sclerosis. Are their presentations different from adult-onset MS? POMS is often associated with higher degrees of activity and inflammation early in the disease. How can clinicians most effectively confirm an early MS diagnosis in these young patients? What does the cu...

Hosted on Acast. See acast.com/privacy for more information.

Has the place for BTK inhibitors in MS been determined? How well do extended interval or alternative B cell depletion dosing regimens work, and for which patients? Do the data support HSCT (hematopoietic stem cell transplant) over high-efficacy DMT — again, for which patients, and with what efficacy and safety? Join us, as guest host Dr. Cole Harrington from the Ohio State University explores thes...

What’s the evidence supporting the existence of an MS prodromal phase — where the biology of the disease has begun but the symptoms typical of MS have not yet appeared? Are there biomarkers to help identify it? Imaging abnormalities? And how can diagnosing a prodrome benefit patients? Join us as we discuss these questions with Dr. Naila Makhani from Yale School of Medicine, in this video podcast i...

Clinicians prescribing the increasingly higher efficacy B-cell depletion or S1P modulators therapies — how aware are they of the newer concerns about safety? Which of their patients may be in greater danger of acquiring PML and/or opportunistic infections? The vaccinations commonly recommended for the general population (eg, COVID-19) — do individuals with MS respond differently, and what should c...

Too many individuals with MS are not receiving access to the most effective care. Why? What’s behind these disparities? And what can individual clinicians do to help remove the barriers that prevent equitable care for all patients? Join us, as Dr. Dorlan Kimbrough, from the division of Neurology, Multiple Sclerosis, and Neuroimmunology at the Duke University School of Medicine, discusses these top...

How burdensome is spasticity for patients with MS? What’s the approach to treatment, and how effective is it? What do patients and clinicians need to know about cannabis-based therapies?   These are the key questions Program Director Dr. Michael Kornberg from the Johns Hopkins School of Medicine discusses with guest MS spasticity experts in this second part of this  e MultipleSclero...

In her  Expert Commentary , Dr. Melanie Ward from West Virginia University’s Rockefeller Neuroscience Institute provided analysis of the newer data describing the modifiable and nonmodifiable risk factors for developing MS and/or increasing the rate of disease progression and disability. Join us for this podcast as Dr. Ward explains how these findings can affect clinical practice to improve o...

How aware are clinicians that MS should no longer be considered a “White people only” disease? What roles have race and ethnicity been shown to play in MS disease severity and disability progression? What do health care professionals need to know to provide the most effective care for all their patients? Join Dr. Yujie Wang from the University of Washington and Dr. Kimystian Harrison, a post docto...

Where’s the newer MS research leading? How has our understanding of noninflammatory progressive MS changed? How might these findings affect what happens in the clinic?  Join us as we discuss these and other questions with Dr. Michael Kornberg from the Johns Hopkins School of Medicine in this  e MultipleSclerosis Review podcast.  Take our  post-test  to claim CME credits. T...

Is it true that a significant number of patients being treated for MS may not actually have the disease? What are the red flags — warnings that something about the patient’s condition does not meet the accepted MS diagnostic criteria — that need to be investigated?    Join us in this  e MultipleSclerosis Review podcast, as Neuroimmunologist Dr. Gabrielle Macaron from Saint Jose...

In this Issue: Fatigue. Urinary dysfunction. Constipation. Spasticity and gait problems. Providing relief from these common MS symptoms often requires clinicians to go beyond the prescription pad to recommend nonpharmacologic treatments. What works? What doesn’t? What does the evidence say?  Join us as Dr. W. Oliver Tobin from the Mayo Clinic discusses these questions in this eMultipleScleros...

As people with MS age, how does their response to their long-term DMT change? Is there a time when disease-modifying therapy can be safely discontinued? In which patients? At what age? What role do comorbidities play in making these decisions?   Join us as we discuss these questions with Dr. Burcu Zeydan from the Mayo Clinic in this  e MultipleSclerosis Review podcast.&nbs...

COVID-19 vaccination. For many people with multiple sclerosis, it’s not a simple and straightforward process. The DMT they’re currently taking to control disease progression and moderate their symptoms — particularly if it’s a beta cell- depleting agent — may prevent the vaccine from working as it’s supposed to. What do clinicians need to know, and how should they explain it to thei...

Shared decision-making — what does it mean in multiple sclerosis? Can it really help providers more fully understand their patients’ concerns? Can it motivate patients to more readily and enthusiastically take ownership of their disease? And most important, how can it be developed in the clinic?  Join us in this  e MultipleSclerosis Review podcast, as we talk about the why and...

As the number of new MS therapies continues to grow, so does the uncertainty about which management approach — escalation or highly effective disease-modifying therapy — is best for each patient. What are the patient-specific factors that indicate the most appropriate DMT selection? What’s known about the potential longer-term risks associated with highly effective th...

A “comprehensive MS center” — what is it? Which clinicians comprise a “multidisciplinary MS care team?” How does comprehensive MS care work in practice? How does it benefit patients? That’s the focus of this non-CME-accredited  e MultipleSclerosis Review podcast, where we answer those questions and more, with our special guest, Dr. Jacqueline Nicholas, System Chief of Neuroimmunology and...

Pediatric multiple sclerosis. How different is the disease from adult MS? Which disease-modifying therapies have been trialed and approved for use in children? How common is cognitive impairment in children with MS? How can it be successfully addressed?   These are some of the important questions Drs. Zongqi Xia and Kavita Thakkar from the University of...

Selecting the most appropriate Disease Modifying Therapy (DMT) is becoming more complicated for patients with MS and clinicians who treat them. Newer approaches and newer agents are altering the benefit/risk equation, and making the question of which treatment is most appropriate for which patient more difficult to answer.  That’s the focus of...

Successful management of multiple sclerosis has gone beyond slowing disease progression and preventing relapses. Improving patients’ health-related quality of life by recognizing and addressing the pervasive chronic symptoms of the disease — spasticity, fatigue, depression, cognitive dysfunction — has become increasingly important. In this  e MultipleSclerosis Review Podcast, Dr. Ba...